Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
M. Rexhepaj, Y.-J. Park, L. Perruzza, D. Asarnow, M. McCallum, K. Culap, C. Saliba, G. Leoni, A. Balmeli, C. Yoshiyama, M. S. Dickinson, J. Quispe, J. T. Brown, M. A. Tortorici, K. R. Sprouse, , D. Veesler
The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.
bioRxiv · Mar 27, 2024 · PreprintBiochemistry
A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran
The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.
bioRxiv · Jan 17, 2023 · PreprintImmunology
R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli
The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.
bioRxiv · Sep 30, 2022Immunology
E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P
This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.
bioRxiv · Dec 12, 2021Immunology
D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave
This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.
bioRxiv · May 9, 2021 · PreprintImmunology
M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom
This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.
bioRxiv · Apr 7, 2021 · PreprintImmunology
T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, , Veesler
This study identifies antibodies against SARS-CoV-2 that balance neutralization potency and breadth, with some showing high resistance to viral escape.
bioRxiv · Apr 6, 2021 · PreprintMicrobiology
M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler
This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.
bioRxiv · Mar 31, 2021 · PreprintImmunology
A. L. Cathcart, C. Havenar-Daughton, F. A. Lempp, D. Ma, M. Schmid, M. L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, , C. M. Hebner
This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.
bioRxiv · Mar 9, 2021 · PreprintImmunology
E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols
The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.
bioRxiv · Nov 4, 2020Microbiology
D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti
This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.
bioRxiv · Apr 7, 2020Immunology